George Warimwe of the Jenner Institute at the University of Oxford in the United Kingdom will develop a vaccine to protect a variety of species, including humans, sheep and cattle, against Rift Valley fever, which can cause serious illness. Current vaccines that are in development have safety concerns for use in humans. They have developed a Rift Valley fever vaccine using a replication-deficient simian adenovirus as a safe vector that is easy and inexpensive to manufacture, and have tested its safety and immunogenicity in mice, and begun field-testing in sheep in Kenya. They will test safety and immunogenicity of the vaccine and the effect of an adjuvant in calves and goats, and compare this with the data from mice and sheep.

Peter Rabinowitz of the University of Washington in the U.S., along with colleagues at Washington State University and CDC Kenya, will test whether unhealthy gut microbes in livestock that co-reside with humans in smallholder households can negatively influence the gut microbes in the humans, and whether this can be exploited to improve human health. The microbial community (microbiota) living in the gut is important for childhood health, growth and development. They will analyze the gut microbiotas of healthy and unhealthy children and co-residing companion and domestic animals in selected households in western Kenya to determine whether they are related. If they are, they will reset the animal microbiota using established fecal transplant methods and determine whether there is a corresponding positive effect on the microbiotas of the rest of the household.

Simon Parrish of Development Initiatives in the United Kingdom will create a toolkit for the generation of a single interoperable dataset from diverse databases to help more users better assess the impact of resource spending in developing countries. Accurately assessing the impact of spending in areas such as health and education in specific locations, and the ability to directly compare different locations, is necessary to effectively eradicate poverty. However, the relevant datasets are currently incompatible or difficult to access by the appropriate communities. Parrish will partner with a Ugandan organization and community leaders in two districts to identify relevant datasets and the pertinent information they contain. This will be used to generate a merged dataset along with a web-based tool for local users, which will then be evaluated for interoperability and usability.

Derek Dunn-Rankin of the University of California, Irvine in the U.S. will refine the design of an energy storage device that collects and stores solar energy to enable indoor or evening cooking in developing countries. Traditional stoves use wood or animal dung as an energy source, which are labor-intensive methods, environmentally unfriendly, and potentially deleterious to health. The storage device consists of an insulated box containing potassium nitrite and sodium nitrite, which undergo a solid-to-liquid phase transition at a certain temperature. During re-solidification, the stored energy is slowly released to provide a stable heat source that can be used to cook foods such as bread and rice. They will work to optimize the design to improve performance and reduce the cost of the device, in order to move towards mass production.

Jean-Pierre Scheerlinck of the University of Melbourne in Australia will develop an effective vaccine against the parasite Theileria parva, which causes East Coast Fever in cattle, by conjugating parasite lysates to nanobeads, which act as an adjuvant to induce a strong immune response. Upon infection, the parasite enters cells of the immune system making classical vaccination strategies that induce antibody responses ineffective. Protecting these animals against infection instead requires a cytotoxic T cell immune response. Nanobeads are inexpensive, inert, 40nm diameter beads that, when covered with antigens, can induce a cytotoxic T cell response in humans. Scheerlinck will generate parasite lysates from infected lymphocytes grown in the laboratory as a source of antigens, conjugate it covalently to nanobeads, and inject them into cattle to test for a robust cytotoxic T cell response and protection against Theileria parva infection.

Ndadilnasiya Endie Waziri of the the African Field Epidemiology Network in Nigeria will determine whether combining child and animal vaccination programs can reduce the incidence of vaccine preventable diseases in Nigeria. Current programs often fail to reach highly mobile rural communities who raise livestock. This dependency on livestock may make them more agreeable to vaccination programs that offer protection for both their animals and themselves, which would also optimize the use of limited health care resources. They will use GPS-enabled smart phones to map these nomadic communities and their movements. A vaccination strategy will be designed, and key workers in the human and animal health sector will be trained to educate the communities and deliver vaccinations against a variety of diseases including polio for humans and anthrax for livestock. Coverage and cost-effectiveness of the strategy will be evaluated.

Kaveh Ashrafi of the University of California, San Francisco in the U.S. will use the free-living model nematode worm Caenorhabditis elegans as a molecular platform to identify new drugs capable of killing adult filarial parasitic worms, which cause serious infections. C. elegans is a non-parasitic model organism that can be easily grown and manipulated in the lab, unlike related parasitic Roundworms. Ashrafi will genetically engineer C. elegans to carry the parasitic version of the gene encoding phosphodiesterase-4, inhibition of which is known to kill the parasites. This mutant, as well as one carrying the human version of the same gene, will be used in screens to identify drug candidates that can selectively kill adult parasites.

Mateus Marrafon and colleagues from Instituto Kairós in Brazil will produce a new system for planting seeds using biodegradable strips of paper to increase productivity and decrease time and labor costs for smallholder farmers in Africa. The seeds are attached to the tape at regular intervals, which improves growth, and the tape physically protects them from pests and high temperatures. They will generate tape prototypes for both manual and animal sowing, and test their performance in the laboratory and in the field. They will also teach individuals how to manufacture and use the seed tape.

Ricardo Capúcio de Resende of Universidade Federal de Viçosa in Brazil will design and test a new machine to enable women smallholder farmers in sub-Saharan Africa to more efficiently and effectively plant seeds. He has designed a new seeder concept using only two rotating parts, which is light, easy to use and maintain, and can simultaneously plant two crops. He will query local manufacturers and users to further develop the design, and then produce prototypes that will be bench- and field-tested for manufacturability and performance. The results will be used to produce the final seeder design, and this design concept could be applied to other agricultural machines.

Thumbi Mwangi of Washington State University in the U.S. will work at the Kenya Medical Research Institute in Kenya to test whether treatment of parasitic helminth infections reduces the severity of the co-occurring parasitic diseases malaria and East Coast Fever (ECF) in humans and cattle respectively, which are more difficult to treat. In many developing countries, humans carry more than one parasitic disease, but if and how they interact to affect disease impact, for example by modifying the immune response, is not well understood. Mwangi will perform a controlled field trial in Western Kenya to test the effect of anthelmintic drugs on the incidence and severity of malaria and ECF, and will also analyze the presence of specific cytokines, which are immune signalling molecules, to help understand how pathogen interactions occur.

Simon Reid and colleagues at the University of Queensland in Australia will develop a combined metric using Multi-Criteria Decision Analysis to integrate divergent values on impacts of disease interventions from the agricultural, animal husbandry, and human health sectors. These sectors are involved in addressing similar issues such as disease control, but they each have different priorities. They will focus on the impact of interventions to reduce the incidence of two diseases in Bangladesh, and use existing data and consultation with stakeholders to identify priorities for intervention, including livelihood impact and livestock productivity, that are then ranked by each sector. This will be used to develop a measurement framework that preserves the priorities for each sector, but provides a means of comparing them and achieving consensus.

Vijay Modi and colleagues of Columbia University in the U.S. will create a universal database to centralize the mapping of social infrastructures, such as schools, clinics, and water points, to improve data accuracy and help to better coordinate aid efforts. Currently, data collection of physical points occurs across multiple platforms, and is inefficient and difficult to update. They will build and host a web service providing a simple database that is easy to access and edit to promote widespread adoption and thereby sharing and integration of important datasets.

Wayan Vota of Development Gateway in the U.S. will combine data generated by citizens and governments into an interactive interface that can be easily accessed and used by average citizens in order to improve their communities. They will focus on education in three Nairobi slums, and engage the local community and government. An application interface will be designed using relevant datasets, such as school performance statistics, community reports, and geographic data, and used to build an interface that can be accessed over the internet or distributed in print form or via messages sent to mobile phones. They will conduct local workshops to test their approach.

Mostafa Zamanian of Iowa State University in the U.S. will take schistosomes, which are parasitic worms that cause a range of infectious diseases, make them sterile, and genetically modify them to deliver anti-parasitic (anthelmintic) agents into humans to protect them against subsequent infections. They will use genome editing, guided by RNA in the worms, to disrupt individual genes required for laying eggs in order to make the worms sterile and thereby non-pathogenic. They will also introduce transgenes that encode for anthelmintic molecules to inhibit parasitic species, including filarial nematodes and juvenile schistosomes, and test their efficacy using animal models. This biological vector system is advantageous as it will specifically target the relevant site in the body and could provide long lasting protection against a variety of parasitic infections.

Willem van Rensburg of Kimbranox Ltd. in South Africa will test a condom applicator, the Rapidom, that is designed for easy, technique-free application of male condoms. Manual application of condoms takes time, which can lead to incorrect positioning as it interrupts the sexual act, and current applicators require good technique. Kimbranox has designed an applicator with an easy, fail-safe design that is applied with one motion, thereby minimizing interruption. An eight-week, randomized, cross-over study will compare ease of application and customer satisfaction between Rapidom and conventionally-packed condoms.

Linda Stewart and Irene Grant of Queen's University, Belfast in the United Kingdom have developed an immunoassay to help determine the incidence of Mycobacterium bovis, which causes tuberculosis in humans and cattle at currently unknown levels. Tuberculosis caused by M.bovis is resistant to a drug commonly used to treat tuberculosis caused by the more prevalent M. tuberculosis, but the diseases are indistinguishable. They have developed a quick and simple test to assay for the presence of M.bovis-specific antigens, which they identified by irradiating a virulent strain to render it inviable while maintaining critical cell surface protein structures. By collaborating with an African institute, they will refine their assay and evaluate its ability to detect M.bovis in human sputum or urine samples.

Floriano Silva of Fiocruz in Brazil will develop a drug screening assay using automated microscopy to test new drug candidates for toxicity towards adult helminth parasites, which cause a range of diseases. Current screening approaches cannot easily identify drugs that specifically target adult parasites, which is the most disease-relevant life cycle stage. He will develop and validate imaging and computational methods to automatically monitor physical characteristics of the parasites, and perform proof-of-principle drug screens using an FDA approved and an annotated compound library. This approach could be expanded to other parasites and used for screening larger drug libraries to identify new classes of drugs.

Andrew Jackson of the University of Liverpool in the United Kingdom will develop a diagnostic tool for Animal African Trypanosomiasis (Nagana), which is caused by unicellular parasites known as trypanosomes and threatens up to 50 million cattle in sub-Saharan countries. To avoid immune detection, the causative trypanosomes change their DNA sequences (genomes), particularly in genes encoding for cell surface glycoproteins, which also affects the symptoms the parasites cause. They will sequence these trypanosome genes from forty parasites spanning diverse countries and hosts to quantify their variation. By associating the variation with disease factors, such as virulence and severity, this profile of variation can be developed as a diagnostic marker to improve disease management and treatment.

Cecilia Bouzat of the Instituto de Investigaciones Bioquímicas de Bahía Blanca in Argentina will develop a drug screening platform to identify new antiparasitic drugs using the model nematode Caenorhabditis elegans. There are limited numbers of effective anthelmintic drugs and resistance to these drugs is emerging in the field. However, parasitic nematodes are unsuitable for large-scale drug screens mainly because they generally require host animals to survive. She will use the related free-living C. elegans to screen extracts of medicinal plants from South America and isolate bioactive compounds from any extracts demonstrated to be toxic for nematodes. The protein targets of these compounds will then be identified and the corresponding DNA from the clinically-relevant nematodes will be incorporated into C. elegans by genetic engineering to validate the compound's anthelmintic activity and enable the testing of derivatives that may be more effective.

Nils Pilotte and Steven Williams of Smith College in the U.S. along with Lisa Reimer at the Liverpool School of Tropical Medicine in the United Kingdom are developing a simple and inexpensive approach to monitor diseases caused by parasites that thrive in mosquitos based on detection in mosquito feces. Current approaches for disease surveillance are expensive, insensitive, or labor intensive, and are generally unsuitable for the areas in which they are needed most, including where disease incidence has decreased. This proposed so-called molecular xenomonitoring approach overcomes these hurdles, in part by avoiding the need for human sampling, and because it can be adapted to increase throughput. In Phase I, they demonstrated proof-of-principle that very low levels of parasitic DNA could indeed be extracted from mosquito fecal samples and then detected by PCR, and also adapted a simple test-strip detection method that could be used in low-resource field settings. They also developed a mosquito trap from a two-liter soda bottle containing a simple carbon dioxide-producing solution and sugar, and demonstrated its ability to attract mosquitos and isolate their feces in a field setting in Trinidad, albeit with modest yields. In Phase II, they will further optimize their detection method and the traps, and perform preliminary field tests in malarial and filarial endemic locations in the Philippines, Ghana, and Haiti.

Milosz Faber of Thomas Jefferson University in the U.S. will develop a combined contraceptive rabies vaccine that both protects dogs against rabies and reduces their population levels in order to control the incidence of human rabies. Human rabies causes 70,000 deaths annually and is mostly spread by dogs. Current therapeutic approaches to control dog rabies require multiple doses and have had limited success. Faber has designed a safe dog rabies variant that can induce a strong and long-lasting immune response when introduced in mice. He will combine this vaccine with gonadotropin-releasing hormone (GnRH), which causes infertility. Three different carrier proteins will be conjugated to GnRH and tested in combination with the vaccine for safety and for inducing immune responses upon a single dose in mice.

Fidelis Cho-Ngwa of the University of Buea in Cameroon will develop a small animal model to test the safety of candidate drugs for treating the parasitic disease onchocerciasis in people who are coinfected with the Loa loa parasite. Ivermectin, which is used in mass drug administration efforts to treat onchocerciasis, causes severe adverse effects, including death, in people who carry high levels of Loa loa. They will purify early-stage Loa loa from infected human blood and test the ability of a variety of small animal models, including mice, to sustain the parasites over 30 days, which would be enough time to perform an in vivo drug screen. Once a suitable small animal model has been identified and validated, it will be possible to screen large numbers of compounds to identify effective and safer treatments.

Mumbi Kimathi and a team from Farm Concern International in Kenya will promote farming-related trade between and around villages in rural Africa with their "e-Women Dial-up Initiative." They will develop a mobile phone platform for communications, and for ordering and paying for farming-related materials, products, and services. They will test their approach in 10 villages in Kenya, consisting of 5,000 farmers, and establish a rural distribution network by recruiting vehicle owners to reduce the need for individuals to be mobile. They will also set up a supply network of accredited materials, services, and business development service providers. Their approach will be evaluated in terms of volumes traded, income, cost- and time-savings, and the level of individual participation.

Geraldine Taylor and colleagues at The Pirbright Institute in the United Kingdom will develop a thermo-tolerant vaccine based on human adenovirus 5 (Ad5) against peste des petits ruminants (PPR), a highly contagious disease found in goats and sheep, that enables the distinction between infected and vaccinated animals (known as DIVA vaccines). Current live attenuated vaccines require cold storage, which is unavailable in many developing countries, and vaccinated animals cannot be differentiated from infected animals, complicating disease control efforts. Ad5–vectored vaccines are safe and effective in humans, inducing both antibody and cytotoxic T cell responses from the immune system. They will extend their preliminary work showing that Ad5-conjugated with surface glycoproteins from the PPR virus provides complete protection in goats by vaccinating local breeds of goats in Africa. They will also determine the minimum vaccine dose and the effect of adding a specific cytokine to enhance immunity.

Edward Mitre and colleagues at the Henry M. Jackson Foundation for the Advancement of Military Medicine in the U.S. will develop a short course therapy for clearing adult filarial worms, which cause substantial morbidity and mortality, to enhance eradication efforts. Current antifilarial medications target only larval forms of the worms, requiring repeated administration until the natural death of the adults. Filarial infections are known to induce immune cells to release histamine, which can regulate the immune response. Using mouse models of filarial infections, they will evaluate whether a short course of standard antifilarial treatment combined with an antihistamine can clear adult worms and thereby more quickly cure the disease.

Ali Mokdad and a team at the University of Washington in the U.S. will integrate data on animal health and its determinants to better understand and monitor human health and opportunity in the developing world. Animal health, which itself is influenced by environmental factors, has a direct impact on human health. Although data on all these areas exist, there has been no attempt to amalgamate them to measure the overall impact on human health. They will assess data from Zambia on environmental factors such as temperature and rainfall, and the condition and sales of animals and crops, to identify indicators of animal health. These will be integrated with data on human disease burden and mortality to generate an enhanced human health metric that incorporates the effects of animal health. They will also make recommendations for improved data collection.

Vandana Patravale of the Institute of Chemical Technology in India will develop a sub-unit nanovaccine using green technology against brucellosis, a zoonotic disease which is endemic in sub-Saharan West Africa. The vaccine will be developed for non-invasive intranasal administration and the investigators will study vaccine delivery and its ability to induce a strong protective immune response against Brucella in mice, with a view to future clinical testing in humans.

Aravind Vijayaraghavan and a team from the University of Manchester in the United Kingdom propose to develop new elastic composite materials for condoms containing nanomaterials like graphene. This composite material will be tailored to enhance the natural sensation during intercourse while using a condom, which should encourage condom use.

Louise Kelly-Hope of the Liverpool School of Tropical Medicine in the United Kingdom and Thomas Unnasch of the University of South Florida in the U.S., along with their research teams, will develop high resolution tools to map the locations and chart the habitats of vectors of several parasitic worm infections to promote safer and more effective control strategies. Some of the drugs that can successfully treat parasite infections become harmful in the presence of other parasites, but predicting where these co-infections are most likely to occur is difficult. Using the fly vectors for the parasitic nematode Loa loa, they will develop a remote sensing model for predicting its presence by identifying environmental factors that the flies favor using satellite technology and geographic information systems, and validate the model by performing ground-based studies in several African countries.

Ron Frezieres of the California Family Health Council in the U.S. along with Max Abadi of Unique International in Colombia and I.MAXX Inc. in the U.S. are developing a stronger and thinner male condom made of polyethylene to promote condom use. Polyethylene is a non-toxic and hypoallergenic material that wraps and clings rather than squeezes, thereby enhancing sensation and enabling easier application. In Phase I, in collaboration with the polyethylene condom inventor/manufacturer in Colombia, the team optimized the material, tested compatibility with different lubricants, designed discreet packaging, and manufactured two prototypes with either a pull-tab applicator or a flanged base.These were compared with traditional latex condoms for performance and usability by 34 couples that overall preferred the pull-tab condom. In Phase II, they will further optimize the condom by improving the lubrication and application, and develop more economical packaging for developing countries. They will also perform a larger clinical study of the modified product using 300 couples.

David Sands of Montana State University in the U.S. will work with Kenyan women farmers to evaluate the performance of a biological control method for eliminating the parasitic weed Striga (witchweed), which can cause up to 80% loss of maize, millet, and sorghum yield in smallholder African farms. Striga is a problem in 43 African countries, and manual weeding is highly time- and labor-intensive. They have previously developed a virulent fungal strain to inhibit weed growth, and shown that it can be easily transported on toothpicks for safe and effective distribution. Preliminary field-tests in one village showed that this fungus could effectively control Striga, and in some instances double crop yield. Sands will expand this testing phase to women maize farmers in 50 villages and evaluate crop yield, weed reduction, and farmer satisfaction over 12 months.

Paula Ribeiro of McGill University in Canada will develop a simple diagnostic test for schistosomiasis, which is caused by parasitic worms, based on microRNAs. Current diagnostics suffer from lack of sensitivity or an inability to distinguish current from past infections. They will evaluate parasite microRNAs contained within small extracellular vesicles (exosomes) as infection biomarkers by first isolating and sequencing them from infected mice. Using this information, they will develop a simple, inexpensive test to amplify the microRNAs from human blood using sera from infected patients in West Africa and Egypt. Their approach could ultimately be used to distinguish between different stages of infection and be broadened to other helminth infections.

Robert Greenberg of the University of Pennsylvania in the U.S., along with Bernadette Ardelli of Brandon University in Canada, will test whether anthelmintics, which are drugs used to treat diseases caused by parasitic worms, can be improved by combining them with inhibitors of ATP-binding cassette (ABC) multidrug transporters. Of the few anthelmintics available, many are of limited use or become ineffective due to the emergence of drug resistance. ABC multidrug transporters regulate the transport of molecules, including drugs, into and out of the cell and have been linked with anthelmintic resistance. ABC transporter inhibitors, which have been approved for use in humans, enhance the activity of anti-parasitic drugs in vitro and may bypass the development of drug resistance. The investigators will use in vivo mouse models of helminth infections to test whether co-administering ABC transporter inhibitors enhances anthelmintic activity, with a view to carrying out clinical trials in humans.

Yanping Chen of the University of California, Riverside in the U.S. will develop an inexpensive and robust sensor to directly measure the real-time density of insect vectors that transmit parasitic diseases to help plan intervention and treatment programs. Preliminary results indicate that insects can be classified based on the frequency of their wingbeats, which also varies depending on the time of day. Chen will develop an accurate detection system by investigating combining wingbeat frequency with circadian rhythms and other behaviors. A software system will also be produced that can translate the data into real-time counts of insect numbers and produce density maps of their distribution. The sensors will be field tested in Cameroon and Cambodia/Thailand.

Tobias Oker and a team from the National Agricultural Research Organization in Uganda will develop a simple plucking tool to more efficiently remove the pods from groundnuts, which is currently done by hand and is labor-intensive and time-consuming for women. They will query farming communities on current harvesting methods to refine their design, and evaluate performance, labor cost, and perceptions in the field using prototypes compared to traditional methods. They will also train users and local manufacturers to fabricate the tools and encourage their use.

William Kisaalita of the University of Georgia in the U.S. will redesign a milk churner to make it suitable for women in order to reduce the time and labor needed to make ghee. In many sub-Saharan countries, the morning milk harvested from cattle can be sold in markets, but the milk harvested in the evening needs to be processed into longer-lasting products such as ghee to prevent it from perishing. The current method for churning milk to make ghee is time and labor intensive. He will recruit women in Uganda to test and refine the milk churner design, which is cheap and can be locally manufactured and repaired, to make it more ergonomic and culturally appropriate for women users and thereby promote its widespread adoption.

Brian Lund and colleagues from Oxfam America in the U.S. will work in Cambodia to increase the use of labor-saving weeders by smallholder women farmers there. Rice cultivation is the primary source of food and income for these households, and weeding crops requires substantial time and physical effort. Cheap, easy to use, and effective mechanical weeders have been developed and tailored for smallholder women rice farmers, but they have yet to be widely adopted due to limited marketing and inadequate local fabrication and distribution capabilities. They will work with a group of local metal fabrication businesses and distributors to demonstrate the profit potential and train them to manufacture the weeders. They will also launch a marketing campaign, including local advertising and demonstrations aimed at women farmers, to stimulate demand.

Population Services International (PSI) proposes to conduct a proof-of-concept study followed by a larger clinical trial in two public sector hospitals through FOGSI in India, to determine if a new intrauterine device (IUD) inserter, specifically designed for the postpartum setting, will improve service delivery. Pregna International will provide the inserters free of cost, and Stanford University will provide technical expertise in study design and implementation. The primary objective of the study is to determine the safety, acceptability (provider/consumer comfort and confidence), feasibility, and efficacy of postpartum intrauterine device (PPIUD) inserters.

Jeffrey Stringer of the University of North Carolina Global Women’s Health group in the U.S. will oversee a team of Zambian and U.S. researchers in a prospective cohort study of 2,000 pregnant women over a three-year period in Lusaka, Zambia. The study will assess gestational age by early ultrasound and collect data and specimens throughout pregnancy and at delivery with standardized systems to document complications of pregnancy and assessment of birth outcomes. Data and specimens will be used to evaluate the causes of preterm birth and investigate novel strategies for prevention.

David Eschenbach and his team from the University of Washington in the U.S. will determine the effect of disturbances in the vaginal microbiome on preterm birth. Their research will investigate how specific vaginal bacterial infections and changes in the female reproductive tract are associated with preterm birth. The long-term goal is to identify new ways for early identification and treatment of women at risk of preterm birth and develop a point-of-care diagnostic test appropriate for low-resource settings, which would function much like a home pregnancy test, indicating an elevated risk of premature birth.

Stephen Oliver and Elizabeth Bilsland at the University of Cambridge in the United Kingdom will develop a yeast-based screen to identify compounds inhibiting selected enzymes from parasitic filarial worms, which cause several common and debilitating diseases. Candidate enzymes as potential antifilarial drug targets will be selected based on their importance specifically in the adult stages of the parasite life cycle, against which current drugs are ineffective. Yeast strains will be modified to produce these candidate enzymes and used in medium-throughput screens with the freely-available Malaria Box of compounds, which are active against the malaria parasite. This approach is cheaper and easier than current screening methods, and should identify compounds that are highly specific for adult filarial worms.

Aaron Maule of Queen's University Belfast in the United Kingdom will develop food crops expressing microRNAs that, upon ingestion by humans, can be used to target and kill parasitic worms and the mosquitos that transmit them. Plant microRNAs can survive the digestion process and are detected in human blood following consumption. Therefore, they may also be encountered by blood-borne parasitic worms and by the blood-eating insects that transmit them, which cause widespread disease. He will select candidate microRNAs and test their activity using rodent infection models. The most effective microRNAs will be tested for toxicity to human cells, and will be used to engineer transgenic plants to analyze efficacy upon ingestion in rodents.

Edward Mitre and his team at the Uniformed Services University in the U.S. will develop a method for the long-term maintenance of parasitic Roundworms (filariae) in cell-free culture. Human filariae cause substantial morbidity worldwide, but current therapies are inefficient or cause harmful side effects. Additionally, the inability to maintain filariae in vitro has hampered screening efforts to identify new drugs. They will determine whether factors secreted by human endothelial cells can prolong the in vitro cell-free survival specifically of adult filariae, which are resistant to some treatments and therefore attractive targets for new therapies.

Paul McVeigh from Queen's University of Belfast in the United Kingdom will develop a diagnostic for filarial infections, which are caused by parasitic nematodes (roundworms) and can cause severe pain and disability. He will screen serum samples from filariasis patients to identify circulating microRNAs associated with the presence specifically of adult parasitic nematodes (macrofilariae) as candidate diagnostic biomarkers. As macrofilariae commonly evade existing diagnostics and are resistant to some treatments, this approach could substantially improve elimination efforts of this highly prevalent disease.

Gregory Goldgof, Elizabeth Winzeler and colleagues from the University of California, San Diego in the U.S. have developed a drug-sensitive yeast strain by deleting the main multi-drug export pumps to help identify the mechanisms of action of the 400 next-generation anti-malarial drug candidates in the Malaria Box. This will help optimize drug safety and efficacy for clinical trials. In Phase I, they successfully screened the Malaria Box compounds and identified 30 that were active in their assay. They also performed directed evolution studies by exposing the yeast to increasing sublethal concentrations of 21 of the active compounds. Resistant yeast clones were then sequenced to identify the likely molecular targets. In Phase II, they will exploit the same yeast strain to identify targets for compounds with activity specifically against either the liver stage of the malaria parasite, which could be used to cure infected patients, or the gametocyte stage, which could reduce the rate of malaria transmission. Their approach is particularly valuable for these types of compounds as they cannot be used for directed evolution studies in the malaria parasites themselves.

Caroline Diehl of Media Trust in the United Kingdom and her team will combine its existing television channel with media partnerships and creative young people to produce the first television, online and mobile channel run by young people to disseminate stories on development. A pilot model has been locally tested using established infrastructure and partnerships. They will form global partnerships for distribution, recruit managers, and build a small team of young reporters and filmmakers from the UK and one or more developing countries, and provide them with a unique platform to create, present, and distribute stories on local and global development.

Ockie Bosch and his team at the University of Adelaide in Australia will create a virtual Evolutionary Learning Laboratory (ELLab) to identify sustainable labor-saving innovations in Sub-Saharan Africa and South Asia. The ELLab is a systems approach designed to incorporate thinking from all relevant groups, such as the farmers, policy makers, and tool developers, in order to define useful, practical, and broadly applicable solutions. They will conduct interviews and run workshops to promote a shared understanding of the needs and viewpoints on labor-saving strategies of the different groups, and build their capacity for thinking more holistically. Proposed solutions, such as new tools, strategies, and policies will undergo a cyclical process of discussions and problem solving, leading to the evolution of more effective labor-saving solutions.

Alice Irene Whittaker-Cumming and Veronica Kette of Mother Nature Partnership and the African Women Education and Development Forum in the U.S. will provide innovative reusable menstrual cups and related education to women smallholder farmers. Current cultural taboos inhibit women from farming while menstruating, substantially reducing productivity. Building on a successful pilot project, they will scale-up testing to 5,000 women smallholder farmers in rural Cameroon to evaluate the impact on productivity and behavior. Local health professionals will be recruited to support the project, and educational workshops will be hosted for participants. Radio will also be used to enhance awareness.

Jason Andrews and colleagues from Massachusetts General Hospital in the U.S. have developed a low-cost handheld device that allows rapid and quantitative detection of Loa loa helminthic parasites in the bloodstream by fluorescent photometry. Quantitative detection is important because individuals with high levels of Loa loa can be fatally sensitive to a widely administered drug used to treat another common parasitic worm Onchocerca volvulans. Conventional detection by microscopy is labor-intensive, time-consuming, and often impractical in the field. They will calibrate the device, and then conduct a pilot study at an established field site.